Active Biotech (ACTI) Company presentation summary

Strategic focus and pipeline overview

• Refocused on specialist disease areas with large unmet medical needs, particularly in oncology and inflammation.

• Pipeline includes tasquinimod for hematological malignancies and laquinimod for inflammatory eye disorders, both with ongoing or recently completed clinical studies.

• Orphan Drug Designation granted for tasquinimod in myelofibrosis and multiple myeloma, providing regulatory and market exclusivity advantages.

• Strategic partnerships with leading institutions and licensing agreements enhance clinical execution and commercialization.

• Strong intellectual property position with patents extending into the 2040s.

Tasquinimod clinical development and market opportunity

• Two ongoing Phase Ib/II trials in myelofibrosis, targeting patients ineligible or intolerant to JAK inhibitors, with interim results expected in 2026 and final results in 2027.

• Demonstrated disease-modifying potential in myelofibrosis and multiple myeloma, with clinical benefit rates and synergy with JAK/BET inhibitors.

• Myelofibrosis represents a $2.9 billion market by 2031, with significant unmet need for disease-modifying therapies.

• Tasquinimod shows efficacy in reducing fibrosis, spleen size, and improving survival in preclinical models.

• Orphan Drug Designation and established CMC documentation support accelerated development and commercialization.

Laquinimod for inflammatory eye disorders

• First-in-class topical hydrogel eye drop formulation for non-anterior non-infectious uveitis, with Phase I safety and biodistribution studies completed.

• Demonstrated ability to reach therapeutic concentrations in both anterior and posterior eye segments within 14 days.

• Addresses significant unmet need as no approved eye drop exists for non-anterior uveitis; market opportunity estimated at $1.5 billion by 2033.

• Robust preclinical and clinical safety data, with patent protection through 2042.

• Continued development planned with partners for registrational Phase II/III studies.